INTARCIATHERAPEUTICS, INC. AMENDEDAND RESTATED INVESTORS RIGHTS AGREEMENT NOVEMBER19, 2004

EX-4.2 6 a2150613zex-4_2.htm EX-4.2

Exhibit 4.2

 

 

INTARCIA THERAPEUTICS, INC.

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

NOVEMBER 19, 2004

 

 



 

TABLE OF CONTENTS

 

 

Page

1. REGISTRATION RIGHTS

2

 

 

 

 

1.1. Definitions

2

 

 

 

 

1.2 Request for Registration

3

 

 

 

 

1.3 Company Registration

4

 

 

 

 

1.4 Obligations of the Company

4

 

 

 

 

1.5 Furnish Information

6

 

 

 

 

1.6 Expenses of Demand Registration

6

 

 

 

 

1.7 Expenses of Company Registration

7

 

 

 

 

1.8 Underwriting Requirements

7

 

 

 

 

1.9 Delay of Registration

8

 

 

 

 

1.10 Indemnification

8

 

 

 

 

1.11 Reports Under Securities Exchange Act of 1934

10

 

 

 

 

1.12 Form S-3 Registration

10

 

 

 

 

1.13 Assignment of Registration Rights

11

 

 

 

 

1.14 Limitations on Subsequent Registration Rights

12

 

 

 

 

1.15 “Market Stand-Off” Agreement

12

 

 

 

 

1.16 Termination of Registration Rights

12

 

 

 

2. COVENANTS OF THE COMPANY

13

 

 

 

 

2.1 Delivery of Financial Statements

13

 

 

 

 

2.2 Inspection

13

 

 

 

 

2.3 Termination of Information and Inspection Covenants

14

 

 

 

 

2.4 Right of First Offer

14

 

 

 

 

2.5 Waiver of Right of First Offer for Series D Preferred Stock

15

 

 

 

 

2.6 FIRPTA Compliance

15

 

 

 

 

2.7 Proprietary Information and Inventions Agreements

16

 

 

 

 

2.8 Termination of Certain Covenants and Rights.

16

 

 

 

 

2.9 Reimbursement of Directors’ Expenses.

16

 

 

 

 

2.10 Negative Covenants.

16

 

 

 

3. MISCELLANEOUS

16

 

 

 

3.1 Amendment and Restatement

16

 

 

 

 

3.2 Successors and Assigns

16

 

 

 

 

3.3 Governing Law

17

 

 

 

 

3.4 Counterparts

17

 

i



 

 

3.5 Titles and Subtitles

17

 

 

 

 

3.6 Notices

17

 

 

 

 

3.7 Expenses

17

 

 

 

 

3.8 Amendments and Waivers

17

 

 

 

 

3.9 Future Investors

17

 

 

 

 

3.10 Severability

17

 

 

 

 

3.11 Aggregation of Stock

18

 

 

 

 

3.12 Delays or Omissions

18

 

 

 

 

3.13 Entire Agreement

18

 

ii



 

INTARCIA THERAPEUTICS, INC.

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 19th day of November, 2004, by and among INTARCIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock (the “Series A Preferred”), the Company’s Series B Preferred Stock (the “Series B Preferred”), the Company’s Series C Preferred Stock (the “Series C Preferred”) and the Company’s Series D Preferred Stock (the “Series D Preferred”) (hereinafter referred to as the “Prior Investors”) listed on Exhibit A hereto, the purchasers of the Company’s Series E Preferred Stock (the “Purchasers”) listed on Exhibit A hereto, and S. MARK MORAN (“Moran”). The Prior Investors and the Purchasers are referred to hereinafter as the “Investors” and each individually as an “Investor.”

 

RECITALS

 

WHEREAS, the Company, the Prior Investors and Moran are parties to that certain Amended and Restated Investors’ Rights Agreement dated as of June 16, 2003 (the “Prior Agreement”) which granted certain registration and other rights to the Prior Investors and to Moran;

 

WHEREAS, the Company, the Prior Investors and Moran desire to amend and restate the Prior Agreement as set forth herein and to receive the rights, and to be subject to the obligations, created pursuant to this Agreement in lieu of the rights and obligations set forth in the Prior Agreement;

 

WHEREAS, the Company proposes to sell and issue up to ninety-nine million (99,000,000) shares of Series E Preferred Stock (the “Series E Preferred”) to the Purchasers pursuant to that certain Series E Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith; and

 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Purchasers to invest funds in the Company pursuant to the Purchase Agreement, the Investors, Moran and the Company hereby agree to enter into this Agreement to amend and restate the Prior Agreement and to set forth their agreements and understanding with respect to the rights granted to Investors by the Company.

 

NOW, THEREFORE, in consideration of the above recitals and the mutual covenants made herein, the parties hereby agree that the Prior Agreement is hereby amended and restated to read in its entirety as follow:

 



AGREEMENT

 

1.                                      REGISTRATION RIGHTS.

 

1.1                               Definitions.  For purposes of this Section 1:

 

(a)                                  The term “Act” means the Securities Act of 1933, as amended.

 

(b)                                  The term “Form S-3” means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC (as defined below) which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 

(c)                                  The term “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.13 hereof.

 

(d)                                  The term “1934 Act” shall mean the Securities Exchange Act of 1934, as amended.

 

(e)                                  The term “Preferred Stock” shall mean the Series A Preferred, the Series B Preferred, the Series C Preferred, the Series D Preferred and the Series E Preferred.

 

(f)                                    The terms “register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document.

 

(g)                                 The term “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Series A Preferred, the Series B Preferred, the Series C Preferred, the Series D Preferred or the Series E Preferred, (ii) the shares of Common Stock issued to Moran; provided, however, that such shares of Common Stock referred to in this clause (ii) shall not be deemed Registrable Securities and Moran shall not be deemed a Holder for the purposes of Sections 1.2, 1.12, 1.14 and 3.8 and (iii) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, option, right or other security which is issued as) a dividend or other distribution with respect to, in exchange for or in replacement of the shares referenced in (i) and (ii) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which his rights under this Section 1 are not assigned, and provided that any such shares issued with respect to, in exchange for or in replacement of the shares referenced in clause (ii) above shall not be deemed Registrable Securities for the purposes of Sections 1.2, 1.12, 1.14 and 3.8.

 

(h)                                 The number of shares of “Registrable Securities then outstanding” shall be determined by the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities.

 

2



 

(i)                                    The term “SEC” shall mean the Securities and Exchange Commission.

 

1.2                               Request for Registration.

 

(a)                                  If the Company shall receive at any time after the earlier of (i) November 19, 2007, or (ii) three (3) months after the effective date of the first registration statement for a public offering of securities of the Company (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction), a written request from the Holders of forty percent (40%) of the Registrable Securities then outstanding that the Company file a registration statement under the Act covering the registration of such percentage of the Registrable Securities then outstanding where the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10,000,000, then the Company shall:

 

(i)                                    within ten (10) days of the receipt thereof, give written notice of such request to all Holders; and

 

(ii)                                effect as soon as practicable, and in any event within ninety (90) days of the receipt of such request, the registration under the Act of all Registrable Securities which the Holders request to be registered, subject to the limitations of subsection 1.2(b), within twenty (20) days of the mailing of such notice by the Company in accordance with Section 3.6.

 

(b)                                  If the Holders initiating the registration request hereunder (“Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to subsection 1.2(a) and the Company shall include such information in the written notice referred to in subsection 1.2(a).  The underwriter will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders.  In such event, the right of any Holder to include his Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein.  All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting.  Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders (other than Moran) thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting.

 

3



 

(c)                                  Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 1.2, a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the Company shall have the right to defer taking action with respect to such filing for a period of not more than one hundred twenty (120) days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than one (1) time in any twelve (12) month period.

 

(d)                                  In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2:

 

(i)                                    After the Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective;

 

(ii)                                During the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a registration subject to Section 1.3 hereof; provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; or

 

(iii)                            If the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.12 below.

 

1.3                               Company Registration.  If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan, a registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities which are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration.  Upon the written request of each Holder given within twenty (20) days after mailing of such notice by the Company in accordance with Section 3.6, the Company shall, subject to the provisions of Section 1.8, cause to be registered under the Act all of the Registrable Securities that each such Holder has requested to be registered.

 

1.4                               Obligations of the Company.  Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)                                  Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its reasonable best efforts to cause such registration

 

4



 

statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to sixty (60) days or until the distribution contemplated in the Registration Statement has been completed; provided, however, that (i) such sixty (60) day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such sixty (60) day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (I) includes any prospectus required by Section 10(a)(3) of the Act or (II) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (I) and (II) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the 1934 Act in the registration statement.

 

(b)                                  Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement.

 

(c)                                  Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them.

 

(d)                                  Use its reasonable best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Act.

 

(e)                                  In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering.  Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.

 

(f)                                    Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.

 

5



 

(g)                                 Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or national quotation system which similar securities issued by the Company are then listed.

 

(h)                                 Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration.

 

(i)                                    Use its reasonable best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities.

 

1.5                               Furnish Information.

 

(a)                                  It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities.

 

(b)                                  The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.12 if, due to the operation of subsection 1.5(a), the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required originally to trigger the Company’s obligation to initiate such registration as specified in subsection 1.2(a) or subsection 1.12(b)(2), whichever is applicable.

 

1.6                               Expenses of Demand Registration.  All reasonable and customary expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Section 1.2, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company (including reasonable fees and reasonable and customary disbursements of one counsel for the selling Holders not to exceed $30,000), shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable

 

6



 

Securities to be registered (in which case all participating holders shall bear such expenses in proportion to the number of shares for which registration was requested), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2; provided further, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2.

 

1.7                               Expenses of Company Registration.  The Company shall bear and pay all reasonable and customary expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.13), including (without limitation) all registration, filing, and qualification fees, printers and accounting fees relating or apportionable thereto and the reasonable fees and reasonable and customary disbursements of counsel for the selling Holders selected by them not to exceed $30,000, but excluding underwriting discounts and commissions relating to Registrable Securities.

 

1.8                               Underwriting Requirements.  In connection with any offering involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine, in their sole discretion, will not jeopardize the success of the offering by the Company (subject to the remainder of this Section 1.8).  If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine, in their sole discretion, is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling Holders according to the total amount of Registrable Securities entitled to be included therein owned by each selling Holder or in such other proportions as shall mutually be agreed to by such selling Holders) but in no event shall (i) the amount of securities of the selling Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless such offering is the initial public offering of the Company’s securities in which case the selling Holders may be excluded if the underwriters make the determination described previously in this sentence and no other stockholder’s securities are included or (ii) notwithstanding (i) above, any shares being sold by a stockholder exercising a demand registration right similar to that granted in Section 1.2 be excluded from such offering.  For purposes of the parenthetical in the preceding sentence concerning apportionment, for any selling Holder which is a holder of Registrable Securities and which is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such holder, or the estates and family members of any such partners, retired partners, members, retired members or stockholders and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single selling Holder, and any

 

7


 

pro-rata reduction with respect to such selling Holder shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such selling Holder, as defined in this sentence.

 

1.9                               Delay of Registration.  No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.

 

1.10                        Indemnification.  In the event any Registrable Securities are included in a registration statement under this Section 1:

 

(a)                                  To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, any underwriter (as defined in the Act) for such Holder and each person, if any, who controls such selling Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Act, or the 1934 Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation by the Company of the Act, the 1934 Act, any state securities law or any rule or regulation promulgated under the Act or the 1934 Act or any state securities law; and the Company will pay to each such Holder, underwriter or controlling person, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the extent (and only to the extent) that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person.

 

(b)                                  To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, or the 1934 Act insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder specifically for use in connection with such registration; and each such Holder will pay any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this subsection 1.10(b), in connection with investigating

 

8



 

or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further, that, in no event shall any indemnity under this subsection 1.10(b) exceed the net proceeds from the offering received by such Holder.

 

(c)                                  Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and reasonable and customary expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to material actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding.  The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.10.

 

(d)                                  If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations.  The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission.  In no event shall any contribution under this subsection 1.10(d) exceed the net proceeds from the Offering received by such Holder.

 

(e)                                  The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise.  No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, which

 

9



 

consent shall not be unreasonably withheld, consent to the entry of any judgment or enter into any settlement, which does not include as an unconditional term thereof, the giving by the claimant or plaintiff to such indemnified party of release from all liability in respect to such claim or litigation.

 

1.11                        Reports Under Securities Exchange Act of 1934.  With a view to making available to the Holders the benefits of Rule 144 promulgated under the Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:

 

(a)                                  make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public;

 

(b)                                  file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and

 

(c)                                  furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form.

 

1.12                        Form S-3 Registration.  In case the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will:

 

(a)                                  promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and

 

(b)                                  as soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this section 1.12: (1) if Form S-3 is not available for such offering by the Holders; (2) if the Holders, together with the holders of any other securities of the Company entitled to

 

10



 

inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $1,000,000; (3) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than sixty (60) days after receipt of the request of the Holder or Holders under this Section 1.12; provided, however, that the Company shall not utilize this right more than once in any twelve (12) month period; (4) if the Company has, within the twelve (12) month period preceding the date of such request, already effected two (2) registrations on Form S-3 for the Holders pursuant to this Section 1.12; or (5) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.

 

(c)                                  Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders.  All expenses incurred in connection with a registration requested pursuant to Section 1.12, including (without limitation) all registration, filing, qualification, printer’s and accounting fees and the reasonable fees and reasonable and customary disbursements of counsel for the selling Holder or Holders and counsel for the Company, but excluding any underwriters’ discounts or commissions associated with Registrable Securities, shall be borne and paid by the Company.  Registrations effected pursuant to this Section 1.12 shall not be counted as demands for registration or registrations effected pursuant to Sections 1.2 or 1.3, respectively.

 

1.13                        Assignment of Registration Rights.  The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities who, after such assignment or transfer, holds at least one million (1,000,000) shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations), provided: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section 1.15 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act.  For the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees of a partnership or limited liability company who are partners, retired partners, members or retired members of such partnership or limited liability company, respectively, (including spouses and ancestors, lineal descendants and siblings of such persons or spouses who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership or limited liability company; provided that all assignees and transferees who would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under this Section 1.

 

11



 

1.14                        Limitations on Subsequent Registration Rights.  From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder (a) to include such securities in any registration filed under Section 1.2 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included or (b) to make a demand registration which could result in such registration statement being declared effective prior to the earlier of either of the dates set forth in subsection 1.2(a) or within one hundred twenty (120) days of the effective date of any registration effected pursuant to Section 1.2.

 

1.15                        “Market Stand-Off” Agreement.  Each Holder hereby agrees that, during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following the date of the first sale to the public pursuant to an effective registration statement of the Company filed under the Act, it shall not, to the extent requested by the Company and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such registration; provided, however, that:

 

(a)                                  such agreement shall be applicable only to the Company’s initial underwritten offering of its securities to the general public (the “IPO”);

 

(b)                                  all officers and directors of the Company enter into similar agreements; and

 

(c)                                  such market stand-off time period shall not exceed one hundred eighty (180) days.

 

In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period.

 

1.16                        Termination of Registration Rights.  No Holder shall be entitled to exercise any right provided for in this Section 1 (i) after five (5) years following the consummation of the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the initial firm commitment underwritten offering of its securities to the general public, or (ii) if the Holder owns less than one percent (1%) of the Registrable Securities and can sell all Registrable Securities held by such Holder in any three (3) month period without registration under SEC Rule 144.

 

12



 

2.                                      COVENANTS OF THE COMPANY.

 

2.1                               Delivery of Financial Statements.  The Company shall deliver to each Investor:

 

(a)                                  as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a schedule as to the sources and applications of funds for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (“GAAP”), and audited and certified by independent public accountants of nationally recognized standing selected by the Company;

 

(b)                                  as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, an unaudited profit or loss statement, schedule as to the sources and application of funds for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter;

 

(c)                                  as soon as practicable, but in any event thirty (30) days prior to the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets and sources and applications of funds statements for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company;

 

(d)                                  such other information relating to the financial condition, business, prospects or corporate affairs of the Company as the Investor or any assignee of the Investor may from time to time reasonably request, provided, however, that the Company shall not be obligated under this subsection (d) or any other subsection of Section 2.1 to provide information which it deems in good faith to be a trade secret or similar confidential information; and

 

(e)                                  with respect to the financial statements called for in subsection (b) of this Section 2.1, an instrument executed by the Chief Financial Officer or President of the Company and certifying that such financials were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment, provided that the foregoing shall not restrict the right of the Company to change its accounting principles consistent with GAAP, if the Board of Directors determines that it is in the best interest of the Company to do so.

 

2.2                               Inspection.  From time to time, the Company shall permit each Investor, at such Investor’s sole expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any information which it reasonably considers to be a trade secret or similar confidential information.  The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions.

 

13



 

2.3                               Termination of Information and Inspection Covenants.  The covenants set forth in Sections 2.1 and 2.2 shall terminate as to Investors and be of no further force or effect upon the earlier of (i) the Company’s IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act or (iii) upon an “Asset Transfer” or “Acquisition” as each is defined in the Company’s Certificate of Incorporation as in effect as of the date hereof (a “Change in Control”).

 

2.4                               Right of First Offer.  Subject to the terms and conditions specified in this Section 2.4, the Company hereby grants to each Major Investor (as hereinafter defined) a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined).  For purposes of this Section 2.4, a “Major Investor” shall mean (i) any Investor who holds at least fifty percent (50%) of the combined investment such Investor has made in the Company pursuant to that certain Series A Preferred Stock Purchase Agreement among the Company and the investors thereto, the Series B Preferred Stock Purchase Agreement among the Company and the investors thereto, the Series C Preferred Stock Purchase Agreement among the Company and the investors thereto, the Series D Preferred Stock Purchase Agreement among the Company and the investors thereto and/or the Purchase Agreement, and (ii) any person who holds or acquires at least ten percent (10%) of the then outstanding shares of Preferred Stock issued pursuant to such agreements.  For purposes of this Section 2.4, an Investor includes any general partners, members and affiliates of an Investor.  An Investor shall be entitled to apportion the right of first offer hereby granted it among itself and its partners, members and affiliates in such proportions as it deems appropriate.

 

Each time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions:

 

(a)                                  The Company shall deliver a notice by certified mail or courier service, such as Federal Express, (“Notice”) to the Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares.

 

(b)                                  By written notification received by the Company, within twenty (20) calendar days after giving of the Notice, the Major Investor may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by such Major Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all the Major Investors.  The Company shall promptly, in writing, inform each Major Investor which purchases all the shares available to it (“Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise.  During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares not subscribed for by the Major Investors which is equal to the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of the

 

14



 

Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares.

 

(c)                                  If all Shares referred to in the Notice are not elected to be obtained as provided in subsection 2.4(b) hereof, the Company may, during the sixty (60) day period following the expiration of the period provided in subsection 2.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the Notice.  If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith.

 

(d)                                  The right of first offer in this paragraph 2.4 shall not be applicable to (i) the issuance or sale of shares of Common Stock (or options therefor) to employees, officers or directors of the Company with the approval of the Company’s board of directors, (ii) the issuance of securities pursuant to the Company’s IPO, or (iii) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities outstanding as of the date hereof.

 

(e)                                  The right of first refusal set forth in this Section 2.4 may not be assigned or transferred, except that (i) such right is assignable by each Holder to any wholly owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the Act, controlling, controlled by or under common control with, any such Holder, and (ii) such right is assignable between and among any of the Holders and (iii) such right is assignable with the consent of the Company, which consent shall not be unreasonably withheld.

 

2.5                               Waiver of Right of First Offer for Series E Preferred Stock.  In accordance with Section 3.8 below, the Major Investors hereby consent to the waiver of the Right of First Offer and any notice requirements set forth in Section 2.4 above in connection with the sale and issuance of up to ninety-nine million (99,000,000) shares of Series E Preferred.

 

2.6                               FIRPTA Compliance.   The Company shall provide prompt notice to New Enterprise Associates 10, Limited Partnership (“NEA 10”) following any “determination date” (as defined in Treasury Regulation Section 1.897-2(c)(1)) on which the Company becomes a United States real property holding corporation.  In addition, upon a written request by NEA 10, the Company shall provide NEA 10 with a written statement informing NEA 10 whether NEA 10’s interest in the Company constitutes a United States real property interest.  The Company’s determination shall comply with the requirements of Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely notice to the Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any successor regulation, that such statement has been made.  The Company’s written statement to NEA 10 shall be delivered to NEA 10 within 10 days of NEA 10’s written request therefor.  The Company’s obligation to furnish such written statement shall continue notwithstanding the fact that a class of the Company’s stock may be regularly traded on an established securities market or the fact that there is no preferred stock then outstanding.

 

15



 

2.7                               Proprietary Information and Inventions Agreements.  The Company will cause each person now or hereafter employed by it or any subsidiary with access to confidential information to enter into a proprietary information and inventions agreement substantially in the form approved by the Board of Directors, and will cause, where appropriate, each consultant of the Company or any subsidiary with access to confidential information to enter into agreements containing customary and appropriate terms regarding such confidential information.

 

2.8                               Termination of Certain Covenants and Rights.  The covenants in Sections 2.6 and 2.7, and the rights of first refusal in Section 2.4 shall terminate and be of no further force or effect upon the earlier of (i) the consummation of an IPO or (ii) a Change in Control.

 

2.9                               Reimbursement of Directors’ Expenses.  Reimbursement for reasonable out-of-pocket expenses of members of the Company’s Board of Directors relating to attendance at the Company’s board meetings shall be made by the Company.

 

2.10                        Negative Covenants.  The Company shall not, without the affirmative consent of a majority of the members of the Board of Directors elected by the holders of Preferred Stock of the Company (i) approve or adopt an annual budget of the Company, (ii) incur indebtedness with an aggregate principal amount in excess of $500,000 (other than indebtedness set forth in an annual budget approved in accordance with this Section 2.10), (iii) make any capital expenditures in excess of $500,000 (other than those capital expenditures set forth in an annual budget approved in accordance with this Section 2.10) or (iv) make or agree or commit to make any expenditure in excess of $1,000,000 (unless such expenditure is specifically set forth in the annual budget under which the Company is then operating and which was approved in accordance with this Section 2.10).

 

3.                                      MISCELLANEOUS.

 

3.1                               Amendment and Restatement.  The Prior Agreement is hereby amended in its entirety and restated herein. Such amendment and restatement is effective upon execution of this Agreement by the Company and the Investors holding at least a majority of the Registrable Securities held by all Investors (as the term is defined in the Prior Agreement). Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby superceded in their entirety and shall have no further force or effect, including any notice of or rights under such Prior Agreement. The rights and covenants contained in this Agreement set forth the sole and entire agreement among the Company and the holders of the Shares on the subject matter hereof and supersede any and all rights granted and covenants made under any prior agreements.

 

3.2                               Successors and Assigns.  Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities).  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,

 

16



 

obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

3.3                               Governing Law.  This Agreement shall be governed by and construed under the laws of the State of Delaware.

 

3.4                               Counterparts.  This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

3.5                               Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

3.6                               Notices.  Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given (A) upon personal delivery to the party to be notified, (B) when sent by confirmed telex or facsimile, if sent during normal business hours of the recipient, if not, then on the next business day, (C) upon deposit with the United States Post Office, by registered or certified mail, postage prepaid or (D) two (2) days after deposit with a recognized overnight delivery courier, specifying first or second-day delivery, with written verification of receipt.  All communications shall be sent and addressed to the party to be notified at the address indicated for such party on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties.

 

3.7                               Expenses.  If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.

 

3.8                               Amendments and Waivers.  Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding.  Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then outstanding, each future holder of all such Registrable Securities, and the Company.

 

3.9                               Future Investors.  The parties hereto agree that without the further consent of any party hereto any future purchaser of shares of Series E Preferred Stock pursuant to the Purchase Agreement shall acquire all rights granted to Purchasers and be subject to all obligations of Purchasers under this Agreement upon execution and delivery of this Agreement by such future investor.

 

3.10                        Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

 

17


 

3.11                        Aggregation of Stock.  All shares of Registrable Securities held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

 

3.12                        Delays or Omissions.  It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance  by another party under this Agreement shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring.  It is further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of the Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing.  All remedies, either under this Agreement by law, or otherwise afforded to any party, shall be cumulative and not alternative.

 

3.13                        Entire Agreement.  This Agreement (including the Exhibits hereto, if any) constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.

 

 

[SIGNATURE PAGES FOLLOW]

 

18



 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

 

INTARCIA THERAPEUTICS, INC.

 

INVESTORS:

 

 

 

 

 

VENROCK ASSOCIATES

By:

/s/Karling Alice Leung

 

 

       Karling Alice Leung, President

 

 

 

 

By:

/s/Bryan Roberts

Address: 2000 Powell Street, Suite 1640
             Emeryville, CA 94608

 

 

As a General Partner or Member

 

 

Print Name:

Bryan Roberts

 

 

 

 

 

 

FOUNDER:

 

VENROCK ASSOCIATES III, L.P.,

 

 

by its General Partner, Venrock Management III LLC

 

 

 

S. MARK MORAN

 

 

 

 

By:

/s/Bryan Roberts

 

 

 

As a General Partner or Member

 

 

 

 

 

 

Print Name:

Bryan Roberts

 

 

 

 

 

 

 

 

VENROCK ENTREPRENEURS FUND III, L.P., by its General Partner, VEF Management III LLC

 

 

 

 

 

By:

/s/Bryan Roberts

 

 

 

As a General Partner or Member

 

 

 

 

 

Print Name:

Bryan Roberts

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP 

 

 

 

By:

NEA Partners 10, Limited Partnership,

 

 

its general partner

 

 

 

 

 

 

 

By:

/s/Eugene A. Trainor, III

, General

 

Partner Eugene A. Trainor, III
Administrative General Partner &
Chief Operating Officer

 

 

 

 

 

NEA VENTURES 2003, L.P.

 

 

 

By:

/s/Pamela J. Clark

 

 

 

 

 

 

Name:

Pamela J. Clark

 

 

 

 

 

 

Title:

Vice President

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

Granite Global Ventures II L.P.

 

 

 

By:

Granite Global Ventures II L.L.C., its
General Partner

 

 

 

 

 

By:

/s/Joel Kellman

 

 

 

Joel Kellman

 

 

Managing Director

 

 

 

 

 

GGV II Entrepreneurs Fund L.P.

 

 

 

By:

Granite Global Ventures II L.L.C., its
General Partner

 

 

 

 

 

By:

/s/Joel Kellman

 

 

 

Joel Kellman

 

 

Managing Director

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

Alta California Partners II, L.P.

 

 

 

 

By:  Alta California Management Partners
II, LLC., its General Partner

 

 

 

 

 

By:

/s/Alix Marduel

 

 

Member

 

 

 

 

 

Alta Embarcadero Partners II, LLC

 

 

 

 

 

By:

/s/Elaine Walker Peny

 

 

Under Power of Attorney

 

 

 

 

 

Alta California Partners II, L.P. New
Pool

 

 

 

 

By: Alta California Management Partners
II, LLC., its General Partner

 

 

 

 

 

 

 

 

By:

/s/Alix Marduel

 

 

Managing Director

 

 

 

 

 

Alta BioPharma Partners II, L.P.

 

 

 

By: Alta BioPharma Management Partners
II, LLC

 

 

 

 

 

By:

/s/Alix Marduel

 

 

Management Director

 

 

 

 

 

Alta Embarcadero BioPharma
Partners II, LLC

 

 

 

 

 

By:

/s/Alix Marduel

 

 

Manager

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

InterWest Partners VI, L.P.

 

 

 

InterWest Management Partners VI, L.L.C.
Its General Partner

 

 

 

 

 

 

By:

/s/Arnold Oronsky

 

 

         Managing Director

 

 

 

 

 

InterWest Investors VI, L.P.

 

 

 

InterWest Management Partners VI, L.L.C.
Its General Partner

 

 

 

 

 

 

By:

/s/Arnold Oronsky

 

 

         Managing Director

 

 

 

 

 

BVCF IV, L.P.

 

 

 

By:   Adams Street Partners, LLC
its general partner

 

 

 

 

 

 

By:

/s/Craig S. Taylor

 

 

 

Craig S. Taylor

 

 

Partner

 

 

 

 

 

Atwood-Edminster Trust, dated 4/2/00

 

 

 

By:

/s/Brian Atwood

 

 

 

Brian Atwood, Trustee

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

 

BSI SA

 

 

 

 

 

 

 

By:

/s/P. Solari

/s/T. Streule

 

 

 

 

 

 

Print Name:

P. Solari

T. Streule

 

 

 

 

 

 

Title:

Vice President

Ass. Vice President

 

 

 

 

 

 

Ontario Teachers Pension Plan Board

 

 

 

 

 

 

By:

/s/Terry Woodward

 

 

 

 

 

 

 

Print Name:

Terry Woodward

 

 

 

 

 

 

 

Title:

Portfolio Manager

 

 

 

 

 

 

 

MOntagu Newhall Associates

 

 

 

 

 

 

By:

 

 

 

 

 

 

 

 

Print Name:

 

 

 

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

Pictet Funds Biotech

 

 

 

 

 

 

 

By:

/s/L. Ramsey

/s/Yves Martignier

 

 

 

 

 

 

Print Name:

Laurent Ramsey Yves Martignier

 

 

 

 

 

 

Title:

Director of the Management Company

 

 

 

 

 

 

G Karin Privatstiftung

 

 

 

 

 

 

By:

 

 

 

 

 

 

 

 

Print Name:

 

 

 

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

Raiffeisen Centrobank AG

 

 

 

 

 

 

By:

 

 

 

 

 

 

 

 

Print Name:

 

 

 

 

 

 

 

 

Title:

 

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

SB Life Science Ventures I, L.P.

 

by its General Partner

 

SB Life Science Partners, L.P.

 

by its General Partner

 

SB Life Science Pte Ltd.

 

 

 

 

 

By:

 

 

 

Kazuhiko Kasai, Director

 

 

 

Bio21 Venture Capital Corp.

 

 

 

By:

/s/Chih-Lung Shen

 

 

 

Print Name:

Chih-Lung Shen

 

 

 

Title:

President

 

 

 

Investor

 

 

 

By:

 

 

 

 

Print Name:

 

 

 

 

Title:

 

 

 

 

Glynn Ventures V

 

 

 

By:

/s/John W. Glynn

 

 

 

Print Name:

John W. Glynn

 

 

 

Title:

Managing Partner

 

 

 

GC&H Investments

 

 

 

By:

/s/John L. Cardoza

 

 

 

Print Name:

John L. Cardoza

 

 

 

Title:

Managing Member

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

Montagu Newhall Global Partners, L.P.

 

 

 

 

By:

Montagu Newhall General Partner, L.P.

 

 

its general partner

 

 

 

 

 

 

 

 

By:

/s/C. Ashton Newhall

 

 

 

 

C. Ashton Newhall, Principal

 

 

 

 

 

 

 

Montagu Newhall Global Partners II,
L.P.

 

 

 

 

By:

Montagu Newhall General Partner II, L.P.

 

 

its general partner

 

 

 

 

 

 

 

 

By:

/s/C. Ashton Newhall

 

 

 

 

C. Ashton Newhall, Principal

 

 

 

 

Montagu Newhall Global Partners II-A,
L.P.

 

 

 

 

By:

Montagu Newhall General Partner II, L.P.

 

 

its general partner

 

 

 

 

 

 

 

 

By:

/s/C. Ashton Newhall

 

 

 

 

C. Ashton Newhall, Principal

 

 

 

 

Montagu Newhall Global Partners II-B
L.P.

 

 

 

 

By:

Montagu Newhall General Partner II, L.P.

 

 

its general partner

 

 

 

 

 

 

 

 

By:

/s/C. Ashton Newhall

 

 

 

 

C. Ashton Newhall, Principal

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

G. Samuel Zucker

 

 

 

 

 

  /s/G.S. Zucker

 

 

 

 

 

 

Howard Chao

 

 

 

 

 

/s/Howard Chao

 

 

 

 

 

 

David Krinsky

 

 

 

 

 

/s/David Krinsky

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 


 

 

Pac-Link Fund

 

 

 

By:

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

FuYu Venture Capital Investment Corp.

 

 

 

By:

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

Shin Sheng Venture Capital Investment
Corp.

 

 

 

By:

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

Tai Yuen Venture Capital Investment Corp.

 

 

 

By:

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

Alliance Investment & Management Corp.

 

 

 

By:

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

 

BRENTWOOD ASSOCIATES VII, L.P.

 

 

 

Brentwood VII Ventures, L.P.,

 

Its General Partner

 

 

 

 

 

By:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

BRENTWOOD AFFILIATES FUND, L.P.

 

 

 

Brentwood VII Ventures, L.P.,

 

Its General Partner

 

 

 

 

 

By:

 

 

 

 

 

Title:

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

DELPHI VENTURES IV, L.P.

 

 

 

 

Delphi Management Partners IV, L.L.C.,

 

Its General Partner

 

 

 

 

 

 

 

By:

 

 

 

Managing Member

 

 

 

 

 

 

 

DELPHI BIOINVESTMENTS IV, L.P.

 

 

 

 

Delphi Management Partners IV, L.L.C.,

 

Its General Partner

 

 

 

 

 

 

 

By:

 

 

 

Managing Member

 

 

 

DELPHI VENTURES III, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

DELPHI BIOINVESTMENTS III, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

PACIFIC GROWTH ENTITIES

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

BANCO UNIONE DE CREDITO

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

BANK JULIUS BAER & CO.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

BANK JULIUS BAER & CO, LTD., ZURICH

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

BANQUE SCS ALLIANCE SA

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

BAY CITY CAPITAL FUND II CO-INVESTMENT FUND, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

BAY CITY CAPITAL FUND II, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

BIM AZIONARIO GLOBALE

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

BIM BILANCIATO

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

PIERANGELO BOTTINELLI

 

 

 

 

 

 

 

 

BSI LUGANO

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

CHARTER ADVISORS FUND IV, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

CHARTER ENTREPRENEURS FUND, IV, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

CHARTER VENTURES IV, L.P.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

NEAL R. CUTLER, M.D.

 

 

 

 

 

 

 

 

ROBERT D. ENGLISH

 

 

 

 

 

 

 

ABHAY VARMA

 

 

 

 

 

 

 

ALBERTO MORALDO

 

 

 

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

ESPERIA PERFORMANCE FUND

 

 

 

 

By:

 

 

 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

FIDURHONE DANIEL VOLLENWEIDER

 

 

 

 

 

 

 

GARFIN SPA

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

PHILIP HOWARD

 

 

 

 

 

 

 

 

 

 

 

 

PHILIP AND SARAH HOWARD

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LGT BANK IN LIECHTENSTEIN AG

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

 

LOMBARD ODIER DARIER HENTSCH & CIE

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

RAHN & BODMER BANK ZURICH

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

SCHWEIZERHALL INVESTMENT LTD.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

 

 

TREFOIL S.A.

 

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

TRIAXIS TRUST AG

 

 

 

By: 

 

 

 

 

 

Print Name:

 

 

 

 

 

Title:

 

 

 

 

 

 

URSULA VOLLENWEIDER

 

 

 

 

 

 

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SIGNATURE PAGE

 



 

EXHIBIT A

 

SCHEDULE OF INVESTORS

 

VENROCK ASSOCIATES

attn: Bryan Roberts

2494 Sand Hill Road
Suite 200
Menlo Park, CA 94025

 

VENROCK ASSOCIATES III, L.P.

attn: Bryan Roberts

2494 Sand Hill Road
Suite 200
Menlo Park, CA 94025

 

VENROCK ENTREPRENEURS FUND III, L.P.

attn: Bryan Roberts

2494 Sand Hill Road
Suite 200
Menlo Park, CA 94025

 

NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP

attn: Mike Raab

2490 Sand Hill Road
Menlo Park, CA 94025

 

NEA VENTURES 2003, LIMITED PARTNERSHIP

attn: Mike Raab

2490 Sand Hill Road
Menlo Park, CA 94025

 

GRANITE GLOBAL VENTURES II L.P.

attn: Joel Kellman

2494 Sand Hill Road, Suite 100

Menlo Park, CA 94025

 

GGV II ENTREPRENEURS FUND L.P.

attn: Joel Kellman

2494 Sand Hill Road, Suite 100

Menlo Park, CA 94025

 

ALTA CALIFORNIA PARTNERS II, L.P.

attn:  Elaine Penny

One Embarcadero Center, Suite 4050

San Francisco, CA  94111

 

ALTA CALIFORNIA PARTNERS II, L.P. NEW POOL

attn:  Elaine Penny

One Embarcadero Center, Suite 4050

San Francisco, CA  94111

 

ALTA EMBARCADERO PARTNERS II, LLC

attn:  Elaine Penny

One Embarcadero Center, Suite 4050

San Francisco, CA  94111

 

ALTA BIOPHARMA PARTNERS II, L.P.

attn:  Elaine Penny

One Embarcadero Center, Suite 4050

San Francisco, CA  94111

 

ALTA EMBARCADERO BIOPHARMA PARTNERS II, LLC

attn:  Elaine Penny

One Embarcadero Center, Suite 4050

San Francisco, CA  94111

 

ATWOOD-EDMINSTER TRUST, DATED 4/2/00

c/o Brian Atwood Trustee

90 Mossbridge Lane

Orinda, CA 94563

Los Angeles, CA 90025

 

BRENTWOOD ASSOCIATES VII, L.P.

attn: Hilary Lottenberg, CFO

11150 Santa Monica Blvd.

Suite 1200

Los Angeles, CA 90025

 

BRENTWOOD AFFILIATES FUND, L.P.

attn: Hilary Lottenberg, CFO

11150 Santa Monica Blvd.

Suite 1200

Los Angeles, CA 90025

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SCHEDULE OF INVESTORS

 



 

DELPHI VENTURES IV, L.P.

attn: Matt Potter

3000 Sand Hill Road
Bldg.  1, Suite 135
Menlo Park, CA 94025

 

DELPHI BIOINVESTMENTS IV, L.P.

attn:  Matt Potter

3000 Sand Hill Road
Bldg.  1, Suite 135
Menlo Park, CA 94025

 

DELPHI VENTURES III, L.P.

attn: Matt Potter

3000 Sand Hill Road
Bldg.  1, Suite 135
Menlo Park, CA 94025

 

DELPHI BIOINVESTMENTS III, L.P.

attn: Matt Potter

3000 Sand Hill Road
Bldg.  1, Suite 135
Menlo Park, CA 94025

 

INTERWEST PARTNERS VI, L.P.

Attn: Arnold Oronsky

2710 Sand Hill Road

Second Floor

Menlo Park, CA  94025

 

INTERWEST INVESTORS VI, L.P.

attn: Arnold Oronsky

2710 Sand Hill Road

Second Floor

Menlo Park, CA  94025

 

GC&H INVESTMENTS

attn: James Kindler

One Maritime Plaza, 20th Floor

San Francisco, CA 94111

 

PACIFIC GROWTH ENTITIES

Four Maritime Plaza

San Francisco, CA 94111

 

BANCO UNIONE DE CREDITO

attn. Abhay Varma

Esperia Capital Management Limited

32 Dover St.

London WIX 3RA, England

 

BANK JULIUS BAER & CO.

attn:  Jean-Pierre Pfenninger

Bahnhofstrasse 36

CH-8010

Zurich, Switzerland

 

BANK JULIUS BAER & CO, LTD., ZURICH

attn. Bernhard Schurmann

Swisspartners Investment Network

AM Schanzengraben 23

Postfach 970

CH-8039

Zurich, Switzerland

 

BANQUE SCS ALLIANCE SA

attn: Andreas Ruegg/Jaime Ballestro

11, route de Florissant

Case postale 3733

CH-1211 Geneva 3

Switzerland

 

BAY CITY CAPITAL FUND II CO-INVESTMENT FUND, L.P.

attn. Kirby Bartlett, Vice President

750 Battery St., Suite 600

San Francisco, CA 94111

 

BAY CITY CAPITAL FUND II, L.P.

attn. Kirby Bartlett, Vice President

750 Battery St., Suite 600

San Francisco, CA 94111

 

BIM AZIONARIO GLOBALE

attn: Robert Contini

Bim Intermobilliare SGR S.P.A.

Via Buozzi 6

Torino 10121

Italy

 

BIM BILANCIATO

attn: Robert Contini

Bim Intermobilliare SGR S.P.A.

Via Buozzi 6

Torino 10121

Italy

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SCHEDULE OF INVESTORS

 


 

PIERRANGELO BOTTINELLI

Residence Victoria A

App. No. 23

3962 Flontana

Switzerland

 

BSI LUGANO

attn: Pierre Botinelli

c/o Quaker Securities

8 Place Bel-Air

CH-1260 Nyon

Switzerland

 

BSI SA

attn: B. Ripamonti

Banca della Svizzera Italiana

Via Magatti 2

CH-6901 Lugano

Switzerland

 

CBG COMPAGNIE BANCAIRE GENEVE

attn: Th. Mory

Avenue de Rumine 20

1005 Lausanne

Switzerland

 

RAIFFEISEN CENTROBANK  AG

A1015 Wien

Tegetthoffstrasse 1 – Fifth Floor

Postfach 272

Vienna, Austria

 

CENTRUM BANK AG, VADUZ

attn: B. Ripamonti

Banca della Svizzera Italiana

Via Magatti 2

CH-6901 Lugano

Switzerland

 

CHARTER ADVISORS FUND IV, L.P.

attn. A. Barr Dolan

525 University Ave., Suite 1400

Palo Alto, CA 94301

 

CHARTER ENTREPRENEURS FUND IC, L.P.

attn. A. Barr Dolan

525 University Ave., Suite 1400

Palo Alto, CA 94301

 

CHARTER VENTURES IV, L.P.

attn. A. Barr Dolan

525 University Ave., Suite 1400

Palo Alto, CA 94301

 

NEAL R. CUTLER, M.D.

R.T. Alamo LLC

8501 Wilshire Blvd., Suite 318

Beverly Hills,CA 90211

 

ROBERT D. ENGLISH

Jasper, L.P.

605 Third Avenue, 19th Floor

New York, NY 10158

 

ESPERIA PERFORMANCE FUND

attn. Abhay Varma

Esperia Capital Management Limited

32 Dover St.

London WIX 3RA, England

 

ABHAY VARMA

Esperia Capital Management Limited

32 Dover St.

London WIX 3RA

England

 

ALBERTO MAROLDA

Esperia Capital Management Limited

32 Dover St.

London WIX 3RA

England

 

FIDURHONE S.A.

attn. Daniel Vollenweider

Rue Muzy, 8

Case Rive 3262

CH-1211 Geneva 3

Switzerland

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SCHEDULE OF INVESTORS

 



 

GARFIN SPA

attn. Abhay Varma

Esperia Capital Management Limited

32 Dover St.

London WIX 3RA, England

 

PHILIP AND SARAH HOWARD

Esperia Capital Management Limited

45 Erpingham Road

London SW15 1BQ

 

PHILIP HOWARD

Esperia Capital Management Limited

45 Erpingham Road

London SW15 1BQ

 

KARIN PRIVATSTIFTUNG

attn. Thomas Honigsberger

M&A Privatbank AG

Rennpasse 6-8

1010 Vienna, Austria

 

LGT BANK IN LIECHTENSTEIN AG

attn: Pfiffner Lorenz

Herrengasse 12

FL-3490 Vaduz

Lichtenstein

Germany

 

LOMBARD ODIER DARIER HENTSCH & CIE

attn: Alexandre Meyer

11, rue de la Corraterie, 1211

Geneva 11,

Switzerland

 

MONTAGU NEWHALL GLOBAL PARTNERS, L.P.

attn: C. Ashton Newhall

4750 Owings Mills Blvd.
Owings Mills, MD 21117

 

MONTAGU NEWHALL GLOBAL PARTNERS II, L.P.

attn: C. Ashton Newhall

4750 Owings Mills Blvd.
Owings Mills, MD 21117

 

MONTAGU NEWHALL GLOBAL PARTNERS II-A, L.P.

attn: C. Ashton Newhall

4750 Owings Mills Blvd.
Owings Mills, MD 21117

 

MONTAGU NEWHALL GLOBAL PARTNERS, II-B,  L.P.

attn: C. Ashton Newhall

4750 Owings Mills Blvd.
Owings Mills, MD 21117

 

ONTARIO TEACHERS PENSION PLAN BOARD
attn:  Terry Woodward

attn:  Michael Padfield

5650 Yonge Street

Toronto, ON M2M 4H5, Canada

 

PICTET FUNDS BIOTECH

attn. Michael Sjostrom

Bd Georges-Favon 29

CH-1204 Geneva

Switzerland

 

RAHN & BODMER BANK ZURICH

attn: Bernhard Shurman

Swisspartners Investment Network

AM Schanzengraben 23

Postfach 970

CH-8039

Zurich

Switzerland

 

SB LIFE SCIENCE VENTURES I, L.P.

c/o:  Softbank Corp, Group Management

1-8-8 Shinkawa, ACROSS Building 2F

Chuo-ku, Tokyo 104-0033, Japan

attn: Yoshihito Osaki

 

with copy to:

SB LIFE SCIENCE EQUITY MANAGEMENT, LLC

attn: Joseph Chow, Managing Director

2180 Sand Hill Road, Suite 400

Menlo Park, CA 94025

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SCHEDULE OF INVESTORS

 



 

BIO21 VENTURE CAPITAL CORP.

c/o Michael Huang

5th Fl., No 143, Sec. 2, Min-Sheng East Road

Taipei, Taiwan, R.O.C.

 

GLYNN CAPITAL MANAGEMENT, LLC

attn: John W. Glynn, Jr.

3000 Sand Hill Road

Building 4, Suite 235

Menlo Park, CA 94025

 

SCHWEIZERHALL INVESTMENT LTD.

No. 1 Seaton Place – P.O. Box 641

St. Helier – Jersey

Channel Islands JE48YJ

 

TREFOIL, S.A.

attn: Joseph C. Lewis

Cay House

P.O. Box N776

Lyford Cay, New Providence

Bahamas

 

PAC-LINK FUND

c/o Pac-Link Management Corp.

attn: Beatrice Chen/Joyce Chen

14th Fl., 2. Tun Hwa South Road, Sec. 2

Taipei, Taiwan, R.O.C.

 

FUYU VENTURE CAPITAL INVESTMENT CORP.

c/o Pac-Link Management Corp.

attn: Beatrice Chen/Joyce Chen

14th Fl., 2. Tun Hwa South Road, Sec. 2

Taipei, Taiwan, R.O.C.

 

SHIN SHENG VENTURE CAPITAL INVESTMENT CORP.

c/o Pac-Link Management Corp.

attn: Beatrice Chen/Joyce Chen

14th Fl., 2. Tun Hwa South Road, Sec. 2

Taipei, Taiwan, R.O.C.

 

TAI YUEN VENTURE CAPITAL INVESTMENT CORP.

c/o Pac-Link Management Corp.

attn: Beatrice Chen/Joyce Chen

14th Fl., 2. Tun Hwa South Road, Sec. 2

Taipei, Taiwan, R.O.C.

 

ALLIANCE INVESTMENT & MANAGEMENT CORP.

c/o Pac-Link Management Corp.

attn: Beatrice Chen/Joyce Chen

14th Fl., 2. Tun Hwa South Road, Sec. 2

Taipei, Taiwan, R.O.C.

 

TRIAXIS TRUST AG

attn: Hans-Peter John

Buerglistrasse 6

CH-8002 Zurich

Switzerland

 

URSULA VOLLENWEIDER

Chu du Marochon

1272 Genolier

Switzerland

 

JPMORGAN CHASE BANK AS CUSTODIAN TO THE BVCF IV, L.P.

c/o Adams Street Partners

attn: Craig Taylor

One North Wacker Drive

Suite 2200

Chicago, IL 60606

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
SCHEDULE OF INVESTORS